Navigation Links
Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium
Date:9/8/2011

s, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact    
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41-(0)21-321-01-11
Fax: +41-(0)21-321-01-69
mwagner@debiopharm.com

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44-(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Lena Evans
Account Executive
Tel:  +1-212-845-4262
Fax: +1-212-845-4260
lena.evans@russopartnersllc.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... OH (PRWEB) January 22, 2015 Crystal Diagnostics ... today that it has received AOAC-PTM Certifications for the six ... O121, and O145; collectively referred to as STEC or the ... 1 colony forming unit (cfu) per 325 g of raw ...
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... 10, 2009, NeoStem, Inc. (NYSE Alternext US: NBS) (the ... "Alternext") indicating that the Company is not in compliance ... "Guide"), which requires a listed company to hold meetings ... Company had announced that it planned to hold a ...
... ITMN ) today announced the pricing of an underwritten ... The last reported sale price of InterMune,s common stock on ... $17.96. The offering is expected to close on or ... All of the shares are being sold by the company.UBS ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today reported financial ... net loss for the second quarter of fiscal 2009,was $4.8 ... of $5.9 million,or $0.23 per share, in the second quarter ... expenses were $4.9 million in the second quarter of fiscal,2009, ...
Cached Biology Technology:NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 7
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Germany, April 29, 2009 / b3c newswire / - ... Target Profiling® technology to identify the protein kinase ... (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 ... arthritis and acute pain. In addition, celecoxib’s anti-proliferative ...
... Danforth Plant Science Center have received two awards totaling ... to do research on novel energy initiatives. At ... ever received on the Danforth Campus. The $15 million ... largest the organization has ever received. Washington University ...
... a seminar at another institution several years ago, ... hostile question: Why bother classifying organisms according to ... dynamics, when molecular techniques had already invalidated that ... in the audience nodding their agreement, Jablonski, the ...
Cached Biology News:KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2DOE makes largest Danforth Campus research award in history 2DOE makes largest Danforth Campus research award in history 3DOE makes largest Danforth Campus research award in history 4DOE makes largest Danforth Campus research award in history 5Analysis finds strong match between molecular, fossil data in evolutionary studies 2
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
... Vybrant Apoptosis Assay Kit #4 ... that occur in the permeability of cell ... both YO-PRO-1 and propidium iodide nucleic acid ... plasma membranes of apoptotic cells and labels ...
Request Info...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
Biology Products: